Lerzeparib

This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AEs) and serious adverse events (SAEs) , pharmacokinetic parameters and antitumor effect of TQB3823 tablets in Chinese adult patients with advanced solid tumors .The study was divided into phase Ia and phase Ib, Phase Ia: Dose escalation period, to evaluate the safety and tolerability of TQB3823 tablets, determine MTD;Phase Ib: Effectiveness exploration period, to expand the safe and effective dose group, and to recommend appropriate dosage and method for subsequent clinical research.

主要目的：评估 TQB3823 片在晚期恶性肿瘤受试者中的安全性和耐受性。 次要目的：评估 TQB3823 片在晚期恶性肿瘤受试者中的药代动力学(PK)特征、 初步有效性；评估与疗效、作用机制、安全性等相关的潜在预测性生物标志物的研究。